Evidence map›Paper›PMID 19105608›Full record

ArticleBiochemistry2009

Differential potencies of naturally occurring regioisomers of nitrolinoleic acid in PPARgamma activation.

Richard L Alexander, Marcus W Wright, Michael J Gorczynski, Pamela K Smitherman, Taro E Akiyama, Harold B Wood, Joel P Berger, S Bruce King, Charles S Morrow

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Nitro Fatty Acids (NOMolecules (Basel, Switzerland) · 2021
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Gas-phase fragmentation analysis of nitro-fatty acids.Journal of the American Society for Mass Spectrometry · 2011
    Article
  8. Endogenous ligands for nuclear receptors: digging deeper.The Journal of biological chemistry · 2010
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Richard L AlexanderDepartment of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27101, USA.
Marcus W Wright
Michael J Gorczynski
Pamela K Smitherman
Taro E Akiyama
Harold B Wood
Joel P Berger
S Bruce King
Charles S Morrow
Wake Forest University · US

Funding

MRP/GST SYNERGY IN MULTIDRUG RESISTANCER01CA070338 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI TOWNSEND, ALAN J · 1996 to 2009
$2.5M
The Nitric Oxide Producing Reactions of HydroxyureaR01HL062198 · NHLBI · WAKE FOREST UNIVERSITY · PI KING, S BRUCE · 2000 to 2010
$2.5M
NCI NIH HHS CA70338NCI NIH HHS R01 CA070338NHLBI NIH HHS HL62198NHLBI NIH HHS R01 HL062198
6 · The paper itself

Abstract

Previous studies demonstrated that the naturally occurring electrophile and PPARgamma ligand, nitrolinoleic acid (NO(2)-LA), exists as a mixture of four regioisomers [Alexander, R. L., et al. (2006) Biochemistry 45, 7889-7896]. We hypothesized that these alternative isomers have distinct bioactivities; therefore, to determine if the regioisomers are quantitatively or qualitatively different with respect to PPARgamma activation, NO(2)-LA was separated into three fractions which were identified by NMR (13-NO(2)-LA, 12-NO(2)-LA, and a mixture of 9- and 10-NO(2)-LA) and characterized for PPARgamma interactions. A competition radioligand binding assay showed that all three NO(2)-LA fractions had similar binding affinities for PPARgamma (IC(50) = 0.41-0.60 microM) that were comparable to that of the pharmaceutical ligand, rosiglitazone (IC(50) = 0.25 microM). However, when PPARgamma-dependent transcription activation was examined, there were significant differences observed among the NO(2)-LA fractions. Each isomer behaved as a partial agonist in this reporter gene assay; however, the 12-NO(2) derivative was the most potent with respect to maximum activation of PPARgamma and an EC(50) of 0.045 microM (compare with the rosiglitazone EC(50) of 0.067 microM), while the 13-NO(2) and 9- and 10-NO(2) derivatives were considerably less effective with EC(50) values of 0.41-0.62 microM. We conclude that the regioisomers of NO(2)-LA are not functionally equivalent. The 12-NO(2) derivative appears to be the most potent in PPARgamma-dependent transcription activation, whereas the weaker PPARgamma agonists, 13-NO(2) and 9- and 10-NO(2), may be relatively more important in signaling via other, PPARgamma-independent pathways in which this family of nitrolipid electrophiles is implicated.

Indexed as

Binding, CompetitiveBreast NeoplasmsCell Line, TumorClone CellsDose-Response Relationship, DrugFemaleGenes, ReporterHumansInhibitory Concentration 50Linoleic AcidsLuciferasesNitro CompoundsNuclear Magnetic Resonance, BiomolecularPPAR gammaRadioligand AssayRosiglitazone10-nitro-9,12-octadecadienoic acidLinoleic AcidsLuciferasesNitro CompoundsPPAR gammaRosiglitazoneThiazolidinediones

Identifiers

PMID19105608
PMCPMC9972884
OpenAlexW2043719831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.